Article Text

Download PDFPDF
Are young infants treated with erythromycin at risk for developing hypertrophic pyloric stenosis?
  1. Nitin Maheshwai
  1. Specialist Registrar (Paediatrics), Oxford Deanery, UK; nitin023@rediffmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

A 5-week-old infant is admitted to a high dependency unit with paroxysmal cough associated with dusky episodes. The severity and frequency of cough paroxysm increases and 48 h later pernasal swab confirms the diagnosis of pertusis. You want to treat the infant with erythromycin. However, you have heard that erythromycin can cause hypertrophic pyloric stenosis in young infants. So you decide to find out more before starting the treatment.

Structured clinical question

Are the young infants (subject) exposed to erythromycin (intervention) at risk for developing hypertrophic pyloric stenosis (outcome)?

Search strategy and outcome

Primary sources

Medline (1951–2006) via Dialog DATA star:

Keywords: erythromycin or maciolides AND pyloric stenosis or infantile hypertrophic pyloric stenosis.

Limits: Human, English.

Outcome

A total of 30 articles were found. All the abstracts were read and six relevant articles were identified for the analysis (table 1).1–6 One systematic review included in the analysis was primarily designed to look at the use of erythromycin as a prokinetic agent in preterm infants.6 Another systemic review7 looking at the use of erythromycin for the same was read but not included …

View Full Text

Footnotes

  • Bob Phillips